CD59 and gestational diabetes: In their commentary, Mcintyre et al. [130] emphasise the need for validation and regulatory approval of alternative, less cumbersome strategies for the diagnosis and classification of GDM by using new non-fasting biomarkers such as plasma glycated CD59, a complement regulatory protein, which is showing promise.